Semaglutide ' A New Pathway ' to CVD Risk Reduction: SELECT Semaglutide ' A New Pathway ' to CVD Risk Reduction: SELECT

The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news